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In 30% of patients, spontaneous resolution of acquired FVIII inhibitors has been described after an average of 21 months. 7 However, in the case of bleeding and high antibody titers, rapid restoration of coagulation is required. This often is not achieved by current immunosuppressive regimen. With regard to novel treatment options, the successful application of 2-chloro-deoxyadenosine has recently been reported. 8 Here, the median time to reach nadir inhibitor titers was 137 days; the median time for a 50% increase in FVIIIc was 117 days. Concerning efficacy of rituximab, data of Wiestner and colleagues suggest a faster FVIII recovery (3-12 weeks) . Despite the promising treatment results with rituximab in several immunoglobulin-mediated disorders, 9 it remains a concern whether the nadir of FVIII inhibitors can be achieved fast enough in high-risk cases.
To maximize treatment efficacy in our critically ill patient, we combined standard immunosuppressive therapy with plasmapheresis and rituximab. Plasmapheresis was intended to rapidly reduce autoantibody levels and allow for infusion of large amounts of plasma with procoagulant activities. Indeed, we experienced a decline in inhibitor titers after initiation of plasmapheresis. Within 25 days, a 200-fold reduction of inhibitors was achieved. Yet, it is of note that the remaining FVIII inhibitor titer of 94 BU still was high enough to cause fatal bleeding.
As the number of B cells at that time had already been markedly reduced, half-life of autoantibodies should be investigated. 10 Whereas the combination of rituximab and plasmapheresis was effective in significantly reducing FVIII inhibitor titer, the autoimmune process with its enormous initial inhibitor burden was not overcome. Given the efficacy of combining rituximab with plasmapheresis, however, we strongly suggest its implementation in the very early clinical course in patients with extremely high antibody titers, when rapid elimination of antibodies is required to prevent fatal bleeding. This combined approach may be one way to solve the clinical problem of life-threatening bleeding upon FVIII inhibitors in the future. Response:
Rituximab in the treatment of acquired factor VIII inhibitors
The letter by Fischer et al highlights the clinical challenge presented by patients with acquired factor VIII (FVIII) inhibitors. Fatal bleeding remains a dreaded complication despite the availability of several hemostatic agents and a choice of immunosuppressive drugs. Their patient had an extremely high FVIII inhibitor titer and was treated initially with prednisone alone for 2 weeks, followed by combination chemotherapy, plasmapheresis, and 2 doses of rituximab. While there was a significant decline in inhibitor titer, the patient succumbed to bleeding complications 4 weeks after the start of polychemotherapy and 2 weeks after the initiation of rituximab. The 4 patients with autoimmune hemophilia that we reported had lower inhibitor titers (5 to 60 Bethesda units [BU]) at presentation. Following treatment with rituximab and prednisone, plus cyclophosphamide in the patient with the highest titer, all had rapid clinical improvement and complete resolution within 3 to 12 weeks. 1 The responses have been durable, lasting to date ϩ 17 to ϩ 22 months without any maintenance treatment. A comparable experience has been reported by Kain et al 2 in a patient who had autoimmune hemophilia for 10 years who was refractory to standard immunosuppressive drugs. Their patient's high titer inhibitor (268 BU) resolved over a 4-month period following 4 weekly doses of rituximab (375 mg/m 2 ) alone and remained less than 1 BU for ϩ 7 months. What should the role of rituximab be in the treatment of patients with FVIII inhibitors? Unfortunately it is unlikely that controlled studies will be possible in this rare disease. Perhaps experiences with this agent in the more common autoimmune disorders, for example immune thrombocytopenic purpura (ITP) 3 and rheumatoid arthritis (RA), 4 may serve to guide treatment decisions in patients with acquired FVIII inhibitors. Similar to the responses in our FVIII inhibitor patients, clinical improvement appears often surprisingly rapid in these autoimmune diseases and does not fully correlate with the resolution of antibody titers. While there are numerous reports that rituximab alone may suffice, it appears, at least for patients with RA, that combination therapy with cyclophosphamide may be superior. 4 Rituximab is not effective in all RA patients and relapse is frequent, occurring typically following B-cell recovery 6 to 9 months from the start of therapy. Patients who relapse after an initial response may respond to second courses of rituximab. The question of maintenance therapy has hardly been addressed.
At this time we would certainly agree with Fischer et al that rituximab should be considered early in the management of patients with active bleeding and/or high titer FVIII inhibitors. In patients with very high antibody burden, it seems appropriate to use combination chemotherapy including prednisone, cyclophosphamide, and rituximab at the time of diagnosis. It is well known that FVIII inhibitors can resolve spontaneously in up to 30% of patients, 5 and prednisone alone or in combination with cyclophosphamide will effect remissions in a substantial proportion of patients. 6 However time to resolution of the antibody with these agents is usually slow, taking months, and prolonged treatment with prednisone and cyclophosphamide may be associated with significant side effects. If the response rate to rituxmab continues to be confirmed, it is likely to be shown cost-effective in those patients who require factor replacement. A full course of 4 weekly doses of rituximab is less expensive than one day of replacement therapy with recombinant FVIII and a fraction of the cost of FVIIa (NovoSeven). In patients with low-titer inhibitors it may not even be necessary to give a full course of 4 doses of rituximab once a clear improvement has been detected. To the editor:
Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in acute myeloid leukemia
The hemoglobin-haptoglobin scavenger receptor (CD163/HbSR) is a monocyte/macrophage-restricted transmembrane protein of the scavenger receptor cysteine-rich family. 1 Antigen expression is related to monocyte/macrophage differentiation, with weak expression on peripheral blood monocytes and abundant expression on the majority of tissue macrophages. [2] [3] [4] To clarify 2,3,5 whether CD163/HbSR is also expressed on leukemic cells committed to the monocytic lineage, we measured cell-surface expression of CD163/ HbSR on leukemic blast cells of 78 patients with acute myeloid leukemia (AML). AML diagnosis was established by morphology and cytochemistry according to French-American-British (FAB) criteria and immunophenotyping. 6 Cases were subclassified as M0 (n ϭ 2), M1 (n ϭ 9), M2, (n ϭ 26), M3 (n ϭ 5), M4 (n ϭ 12), M5 (n ϭ 19), M6 (n ϭ 4), and M7 (n ϭ 1). Density gradient-separated peripheral blood mononuclear cells were stained with fluorescein isothiocyanate (FITC)-labeled anti-CD163 antibody (clone 5C6-FAT; BMA Biomedicals, Augst, Switzerland) or an isotype control antibody (BD Biosciences, Heidelberg, Germany) for measurement of cell-surface CD163/HbSR expression by flow cytometry. Of 47 patients with AML subtypes other than M4 or M5, 41 (87%) had no or only minimal expression of CD163/HbSR (Figure 1 ). In the remaining 6 patients, 5% to 8% of the leukemic blasts stained positively for the antigen when compared with the isotype control antibody. In none of the patients, however, did antigen expression exceed 8%. By comparison, 3 of 12 patients with AML M4 and 16 of 19 patients with AML M5 had CD163/HbSR expression 10% or higher (Figure 1 ). At the time of initial diagnosis, 2 patients with AML M5 were treated with glucocorticoids, drugs that are known to increase CD163/HbSR expression on normal macrophages; 7 their effect on antigen expression on malignant cells is, however, unknown.
In line with this lineage-restricted antigen expression, we observed strong correlations between CD163/HbSR and other markers predominantly found in monocytic leukemia, 8,9 such as CD14, CD64, and lysozyme (Table 1) . Weaker correlations were found between CD163/HbSR and the myeloid markers CD15, CD33, CDw65, the percentage of unspecific esterase-positive blast cells, and transcobalamin II 10 (Table 1) , but not for CD13 and CD117 (not shown). In addition, weak inverse correlations were found between CD163/HbSR expression and positivity of cytochemical staining for peroxidase and chloroacetate esterase and flow cytometric detection of intracellular myeloperoxidase (not shown), markers which are usually not expressed by monocytic leukemias. 6 A weak correlation was also found for CD163/HbSR and blood levels of C-reactive protein, possibly reflecting the acute-phase regulated expression of CD163/HbSR.
In conclusion, these results confirm early studies 2,3 and demonstrate that CD163/HbSR is expressed not only on mature monocytes and macrophages but also on leukemic cells. We found the antigen exclusively on the majority of monocytic and a significant subset of myelomonocytic leukemias, suggesting that the restriction of CD163/HbSR expression to cells committed to the monocytic lineage is preserved beyond malignant transformation; this 
